It has been demonstrated that the mucosal administration of polyI:C, a TLR3 ligand, after vaccination with cold-adapted influenza vaccine significantly increased the activation and migration of antigen-bearing TLR3+ CD103+ respiratory DCs to the mediastinal lymph nodes, the generation of influenza-specific CD8 T cells, and the production of neutralizing antibodies [57]. This evidence concerns the gene TLR3 and influenza.